TargetingTherapy with Recombinant Drugs Against Angiogenesis in Cancer

TargetingTherapy with Recombinant Drugs Against Angiogenesis in Cancer
Arezoo Valipour,^1,* Roghaye Arezumand,²
1. North Khorasan University of Medical Sciences,Bojnourd, Iran
2. North Khorasan University of Medical Sciences,Bojnourd
Introduction: Angiogenesis is a physiological pathway by which new blood vessels form the existing vessels. Solid tumors require blood if they grow to more than a few millimeters in size. These new vessels are triggered by various stimuli such as hypoxia, vascular injury or angiogenesis growth factors that act as environmental stimuli. This process must be controlled under harsh conditions, and loss of balance may cause pathological distress such as tumorigenesis. Tumor angiogenesis is one of the main features of cancer cells, whereby new blood vessels are formed adjacent to the tumor. New blood vessels thus supply "growing tumors" with oxygen and nutrients; And cancer cells invade surrounding tissue, move throughout the body. Therefore, rearrangement of angiogenesis factors stimulates tumor growth and metastasis. These angiogenic properties have strengthened the anti-angiogenic therapeutic target with recombinant drugs.
Methods: In this review article, the keywords "therapeutic targeting" AND"recombinant drugs" OR "cancer" AND "angiogenesis". Search PubMed, ScienceDirect and Google Scholar databases
Results: Due to the importance of the angiogenic process in cancer, in this article, the achievements and factors related to the targeting therapy against angiogenesis and the future perspective of cancer therapy by anti angiogenesis agents was reviewed
Conclusion: Angiogenesis targeting is more effective in cancer treatment. In addition the use and sale of these recombinant drugs has increased in recent years, this is a one reason for the success of recombinant drugs.
Keywords: TargetingTherapy،Recombinant Drugs ،Cancer، Angiogenesis